WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of VIROPHARMA INC (VPHM)

Name VIROPHARMA INC
Year low 14.62
Year High 31.00
Symbol VPHM
Last trade 30.50
Percentage change 0.00
Volume 1,434,285
Media Volume (3m) 1,192,580
PE Ratio 20.62
EPS 1.479
Market Cap 2152
Media fatt 531
Trend fatt trend fatt graph for VIROPHARMA INC
Media net income 116
Trend net income trend net income for VIROPHARMA INC
P / E P / E graph for VIROPHARMA INC - 11 points 11
EPS EPS graph for VIROPHARMA INC - 14 points 14
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for VIROPHARMA INC - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for VIROPHARMA INC - 7 points 7
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for VIROPHARMA INC - 11 points 11
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for VIROPHARMA INC - 12 points 12
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for VIROPHARMA INC - 3 points 3
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for VIROPHARMA INC - 6 points 6
NET INC1/NET INC3 net inc1/net inc3 graph for VIROPHARMA INC - 1 points 1
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for VIROPHARMA INC - 3 points 3
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for VIROPHARMA INC - 1 points 1
. . graph for VIROPHARMA INC - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for VIROPHARMA INC - 4 points 4
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for VIROPHARMA INC - 2 points 2
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for VIROPHARMA INC - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for VIROPHARMA INC - 1 points 1
. . graph for VIROPHARMA INC - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for VIROPHARMA INC - 0 points 0
SINTESE 76

GRAPHS

max price logarithm graph for VIROPHARMA INC based on no conditions max volume linear graph for VIROPHARMA INC based on no conditions

News

ViroPharma Provides Update on Industrial Scale Supplement for Cinryze® (C1 Esterase Inhibitor [Human]) (Feb 07 - reuters) 2 Biotech Stocks Leading This Rally (Feb 03 - reuters) Halozyme's New High (Feb 02 - reuters) Is ViroPharma's Growth for Real? (Jan 20 - reuters) Widespread Potential For Halozyme (Jan 17 - reuters) Biotechs: Has The Law Of Gravity Been Suspended? (Jan 13 - reuters) Health Canada Grants Priority Review Status For New Drug Submission (NDS) For Cinryze™ (C1 Inhibitor [human]) (Jan 13 - reuters) 8 Stocks Hitting New Highs Today (Jan 06 - reuters) ViroPharma Provides 2012 Outlook (Jan 06 - reuters) ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors (Jan 04 - reuters) ViroPharma Is Poised For Gain (Jan 01 - reuters) Too Early for a New Biotech Orphan? (Dec 30 - reuters) ViroPharma Completes Acquisition of DuoCort Pharma AB (Dec 23 - reuters) ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma (Dec 23 - reuters) ViroPharma Announces Approval of Modernized Labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules (Dec 23 - reuters) ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) (Dec 23 - reuters) ViroPharma to Participate in Two December Healthcare Investor Conferences (Dec 23 - reuters) DuoCort Pharma's Orphan Drug Plenadren® Granted European Marketing Authorization for Adrenal Insufficiency (Dec 23 - reuters) ViroPharma to Participate in Two November Healthcare Investor Conferences (Dec 23 - reuters) ViroPharma Incorporated Reports Third Quarter 2011 Financial Results (Dec 23 - reuters) ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline (Dec 23 - reuters) ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011 (Dec 23 - reuters) ViroPharma buys right to acquire Meritage Pharma (Dec 23 - reuters) 7 Fallen Angels With Fresh Insider Buying (Oct 07 - reuters) Intellect Neurosciences and ViroPharma Announce $126.5 Million Global Licensing Agreement... (Sep 30 - reuters) ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia (Sep 30 - reuters) Insiders Trading XCO, XIDE, VPHM, NNVC (Sep 27 - reuters) Matching Supply and Demand Is Easier Said Than Done (Sep 23 - reuters) ViroPharma Expands Its Innovative "HAE and Me" Online Community With Education and Support to Meet Unique Needs of (Sep 15 - reuters) ViroPharma Announces Additional Securities Repurchase Program (Sep 15 - reuters) ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) (Sep 14 - reuters) Drug Launches: It's All About Expectations (Sep 13 - reuters) ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) (Sep 13 - reuters) ViroPharma's Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures (Sep 06 - reuters) Shire Enters a Crowded Market (Sep 01 - reuters) ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference (Aug 31 - reuters) ViroPharma Incorporated Reports Second Quarter 2011 Financial Results (Jul 28 - reuters) Is Alexion Pharmaceuticals the Perfect Stock? (Jul 22 - reuters) ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011 (Jul 21 - reuters) » More VPHM.O Market Views (Jul 15 - reuters) ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union (Jun 24 - reuters) ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) (Jun 15 - reuters) Nine Abstracts Relating to Cinryze® (C1 Esterase Inhibitor [human]) Data Presented at 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI) (Jun 13 - reuters) ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference (Jun 02 - reuters) Down! Up! Which Way Will Optimer Go Next? (May 31 - reuters) Optimer Prices New Antibiotic at Premium (May 31 - reuters) Labeling and Script Use May Cause Problems For Optimer's New Drug (May 26 - reuters) ViroPharma Launches 'Swell,' an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema (May 26 - reuters) ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) (May 19 - reuters) ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor (May 11 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY